CD7 and acute lymphoblastic leukemia: In particular, the CD7 antigen was found to be expressed in 30% of de novo AML and some authors proposed to use the ectopic expression of this antigen for planning AML blasts specific CAR-T therapy Identifying common traits between AML and T-ALL in terms of lncRNA could open a novel scenario to investigate on altered pathways leading to leukemogenesis and characteristics of aggressiveness [46].